Last updated: September 2, 2026
Dolutegravir sodium/rilpivirine hydrochloride is the two-drug, once-daily HIV-1 regimen marketed by ViiV Healthcare and Janssen as Juluca. The product targets virologically suppressed adults without prior treatment failure or known resistance to either active ingredient. Its commercial position is durable but constrained by competition from higher-growth two-drug and long-acting regimens, especially Dovato and Cabenuva. U.S. generic entry risk is primarily a post-2027 issue, with the timing affected by Orange Book patents, pediatric exclusivity, and any successful Paragraph IV litigation.
What is dolutegravir/rilpivirine and how is it marketed?
Juluca contains 50 mg of dolutegravir and 25 mg of rilpivirine in a film-coated tablet taken once daily with a meal. Dolutegravir is an integrase strand transfer inhibitor. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor. The regimen is approved for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen and have no history of treatment failure or resistance to either component.[1]
ViiV Healthcare commercializes the dolutegravir component. Janssen developed and commercialized rilpivirine, which is also marketed in Edurant and in other combination products. Juluca is therefore supported by two established commercial franchises rather than by a new molecular entity with independent market development requirements.
| Product |
Active ingredients |
Company relationship |
U.S. approval |
| Juluca |
Dolutegravir/rilpivirine |
ViiV Healthcare and Janssen |
2017 |
| Tivicay |
Dolutegravir |
ViiV Healthcare |
2013 |
| Edurant |
Rilpivirine |
Janssen |
2011 |
| Dovato |
Dolutegravir/lamivudine |
ViiV Healthcare |
2019 |
| Cabenuva |
Cabotegravir/rilpivirine |
ViiV Healthcare and Janssen |
2021 |
The product is administered with food and is not interchangeable with standard three-drug antiretroviral regimens without clinical assessment. Its principal commercial value is regimen simplification for patients already controlled on therapy.
How large is the Juluca market and what is the financial trajectory?
Juluca has developed into a billion-pound global brand for the ViiV/GSK HIV business. GSK annual reports show sustained growth through 2023 and 2024, despite broader pressure on older dolutegravir-based products. Reported sales were approximately £1.0 billion in 2023 and approximately £1.1 billion in 2024.[2,3]
| Metric |
2022 |
2023 |
2024 |
| Global Juluca sales |
Approximately £0.9 billion |
Approximately £1.0 billion |
Approximately £1.1 billion |
| Growth profile |
Expansion |
Double-digit growth reported by GSK |
Continued growth |
| Main commercial driver |
Switch treatment |
Two-drug regimen adoption |
Retention and switching in suppressed patients |
Juluca’s financial trajectory differs from that of a newly launched HIV product. Revenue depends on patient switching, treatment persistence, reimbursement, and the ability to retain patients who are eligible for two-drug therapy. It does not rely primarily on treatment-naive initiation.
The product also benefits from the scale of the dolutegravir franchise. Physicians familiar with Tivicay, Triumeq, and Dovato already understand dolutegravir’s efficacy and resistance profile. That reduces adoption friction for Juluca, although it also creates internal competition within ViiV’s portfolio.
What is driving Juluca demand?
Switching from three-drug regimens
The central demand driver is switching virologically suppressed patients from three-drug therapy to a two-drug regimen. Clinical studies such as SWORD-1 and SWORD-2 supported maintenance of virologic suppression after switching to dolutegravir/rilpivirine.[4]
Switching can reduce exposure to nucleoside reverse transcriptase inhibitors and may appeal to patients seeking a lower-pill-burden regimen. The eligible population is narrower than the total treated HIV population because patients with resistance, prior virologic failure, active hepatitis B infection requiring tenofovir, or unsuitable treatment histories may not qualify.
Portfolio positioning against Dovato
Dovato is the closest internal competitor. It combines dolutegravir with lamivudine and is approved for treatment-naive adults as well as selected virologically suppressed patients. That gives Dovato a larger addressable initiation market.
| Factor |
Juluca |
Dovato |
| Second agent |
Rilpivirine |
Lamivudine |
| Primary use |
Maintenance switch |
Treatment initiation and maintenance |
| Food requirement |
Must be taken with a meal |
No comparable meal requirement |
| Hepatitis B limitation |
Rilpivirine does not provide HBV activity |
Lamivudine alone is inadequate for HBV treatment |
| Commercial position |
Established switch brand |
Higher-growth two-drug platform |
Juluca remains clinically useful where rilpivirine is appropriate, but Dovato has broader prescribing flexibility. ViiV’s portfolio economics favor Dovato in many new-patient settings and Juluca in maintenance-switch settings.
Pressure from Cabenuva
Cabenuva combines long-acting cabotegravir and rilpivirine and is administered by injection after oral lead-in or direct-to-inject initiation under approved conditions. It addresses adherence and pill-burden concerns that Juluca addresses with an oral tablet.
Cabenuva is commercially complementary in some patients but competitive in others. Its higher administration complexity, injection-site reactions, clinic logistics, and reimbursement requirements limit complete substitution. Its growth rate has been stronger than Juluca’s, making it a major factor in the long-term allocation of HIV treatment spending.
When does dolutegravir/rilpivirine lose exclusivity?
The principal U.S. loss-of-exclusivity risk begins in the late 2020s. Dolutegravir and rilpivirine have separate patent histories, while Juluca has combination-product and regulatory protections that must be assessed independently.
| Protection category |
Commercial relevance |
Expected risk window |
| Dolutegravir compound and related patents |
Protects the higher-value integrase component |
Primarily through 2027, subject to extensions and listing details |
| Rilpivirine compound and formulation patents |
Protects the second active ingredient and related products |
Late-2020s timing varies by patent and product |
| Juluca combination patents |
May delay or complicate fixed-dose generic entry |
Potentially beyond core compound expirations |
| FDA exclusivity |
Supports the approved combination after launch |
Original period largely expired |
| Pediatric exclusivity |
Can add six months to qualifying patent or exclusivity periods |
Must be checked against the applicable listed patents |
The FDA Orange Book should be used as the operative source for current U.S. patent listings, expiration dates, pediatric extensions, and any delisting activity.[5] A generic company could challenge one or more listed patents through an Abbreviated New Drug Application with a Paragraph IV certification.
A generic version of dolutegravir alone would not automatically create a generic substitute for Juluca. Fixed-dose combination applicants must demonstrate pharmaceutical equivalence, bioequivalence, manufacturing consistency, and compliance with each applicable listed patent.
What is the Orange Book status of Juluca?
Juluca is an FDA-approved small-molecule fixed-dose combination listed under NDA 210192. It is not a biologic and therefore has no biosimilar pathway. Generic competitors would file ANDAs, not biosimilar applications.
The key Orange Book issues are:
- Whether patents covering the fixed-dose combination remain listed.
- Whether applicants challenge the dolutegravir, rilpivirine, or Juluca-specific claims.
- Whether a patent has pediatric exclusivity attached.
- Whether a court judgment or settlement changes the effective launch date.
- Whether the generic applicant seeks approval for the same indication, strength, dosage form, and route.
The regulatory exclusivity associated with Juluca’s new combination approval has expired. Patent rights, rather than new-drug exclusivity, control the remaining U.S. entry barrier.[5]
Which companies are challenging Juluca and what generic entry risks exist?
Publicly visible competitive risk is greater from internal and adjacent branded products than from a confirmed commercial Juluca generic. Potential ANDA applicants include large generic manufacturers with established antiretroviral operations, such as Teva, Mylan/Viatris, Dr. Reddy’s, Cipla, and Aurobindo, although an applicant’s existence, Paragraph IV filing, or launch date must be confirmed through FDA and court records.
The most likely U.S. launch scenarios are:
Scenario 1: No early Paragraph IV challenge
Juluca remains protected by the latest enforceable patent or regulatory barrier. Revenue declines gradually as physicians move eligible patients to Dovato, Cabenuva, or other newer regimens.
Scenario 2: Paragraph IV challenge with settlement
The innovator and generic applicant agree to a delayed entry date. This is a common commercial outcome in pharmaceutical patent disputes and can preserve branded revenue while granting the generic a defined launch path.
Scenario 3: Successful invalidity or non-infringement challenge
A court ruling could permit earlier entry. The commercial effect would be significant because fixed-dose combination products can lose substantial volume rapidly after generic launch, particularly in price-sensitive public and institutional channels.
Scenario 4: Authorized generic or licensed entry
The patent holder could license supply or introduce an authorized generic to retain channel control. Such a strategy would protect some volume but would reduce the branded product’s net price.
How strong is the Juluca patent estate?
The estate is stronger as a portfolio of component, combination, formulation, and regulatory rights than as a single product patent. Dolutegravir’s commercial importance increases the value of patents covering the integrase inhibitor, but it also creates a pathway for generic companies to attack the components separately.
Patent strength is highest where claims cover:
- The specific fixed-dose combination.
- Stable tablet formulations.
- Manufacturing processes that improve impurity control or dissolution.
- Approved treatment methods for virologically suppressed patients.
- Commercially necessary strengths and dosage forms.
Method-of-use patents are more vulnerable than composition-of-matter claims because generic applicants may use section viii statements to omit patented indications where permitted. Formulation patents can be useful against a fixed-dose product, but their enforceability depends on claim construction, bioequivalence, and whether non-infringing formulations are feasible.
Outside the United States, entry timing varies by national patent validation, supplementary protection certificates, pediatric extensions, tender systems, and local litigation. European markets may experience earlier price erosion than the United States because centralized commercial pressure and national tendering can accelerate switching after patent expiry.
What manufacturing and intellectual-property barriers affect competition?
A generic manufacturer must reproduce a tablet containing two chemically distinct active ingredients while meeting dissolution, content uniformity, stability, and impurity specifications. The technical challenge is manageable for experienced antiretroviral manufacturers but can increase development cost and regulatory risk.
The main barriers are:
- Sourcing GMP-grade dolutegravir sodium and rilpivirine hydrochloride.
- Controlling polymorphism and particle-size effects.
- Demonstrating bioequivalence for the fixed-dose tablet.
- Matching food-effect characteristics.
- Establishing stability across global climatic zones.
- Managing separate patent risks for the two active ingredients.
- Securing procurement access in countries dominated by government tenders.
These barriers support a gradual rather than immediate global erosion pattern, unless a major generic supplier secures broad regulatory approvals and aggressive tender contracts.
What is the revenue exposure from generic entry?
Juluca’s revenue exposure is material because the product has reached approximately £1 billion in annual global sales. The largest risks are United States price erosion, European tender substitution, and internal migration to Dovato or Cabenuva.
A rapid U.S. generic launch could reduce branded volume and net price within the first year. A delayed or market-specific launch would produce a slower decline because ViiV could retain patients through brand loyalty, contracting, and clinical familiarity.
The most defensible revenue remains in markets where Juluca is embedded in treatment guidelines, reimbursement formularies, or public procurement systems. The least defensible revenue is in markets where treatment decisions are highly price-driven and generic suppliers already have established HIV distribution.
Key Takeaways
- Juluca is the branded dolutegravir/rilpivirine fixed-dose tablet marketed by ViiV Healthcare and Janssen.
- The product is approved for virologically suppressed adults without relevant resistance or treatment failure.
- Global sales reached roughly £1.0 billion in 2023 and £1.1 billion in 2024 based on GSK reporting.
- Dovato is the closest branded competitor because it combines dolutegravir with lamivudine and has broader treatment-initiation use.
- Cabenuva creates additional pressure through long-acting injectable delivery.
- The primary U.S. generic risk window begins in the late 2020s, subject to current Orange Book patents, extensions, litigation, and settlements.
- Juluca is a small-molecule product, so biosimilar competition is not applicable.
- Fixed-dose formulation, manufacturing, and combination patents may extend practical protection beyond the earliest component patent expirations.
- A Paragraph IV settlement is more likely to produce a defined delayed-entry date than an immediate generic launch.
- Revenue erosion is likely to be gradual before patent-driven entry because internal portfolio switching is already a major competitive force.
FAQs
Is Juluca the same as dolutegravir alone?
No. Juluca contains dolutegravir and rilpivirine. Dolutegravir alone is marketed primarily as Tivicay and is used with other antiretroviral medicines.
Can Juluca treat HIV patients with hepatitis B?
Juluca does not provide a complete hepatitis B treatment backbone. Patients with HIV and hepatitis B generally require an antiretroviral regimen containing agents active against both viruses.
Is there a biosimilar version of Juluca?
No. Juluca is a small-molecule tablet. Competition would arise through an ANDA-approved generic, not a biosimilar application.
Does a generic Tivicay launch automatically create generic Juluca competition?
No. A generic dolutegravir product is not equivalent to the fixed-dose dolutegravir/rilpivirine tablet. A Juluca generic must satisfy separate combination-product requirements.
Which product has greater long-term growth potential, Juluca or Dovato?
Dovato has greater structural growth potential because it has broader treatment-initiation use and fewer food-related administration constraints. Juluca remains commercially valuable as a maintenance-switch product with an established patient base.
References
- U.S. Food and Drug Administration. (2017). Juluca prescribing information. https://www.accessdata.fda.gov
- GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-report/
- GSK plc. (2025). Annual report 2024. https://www.gsk.com/en-gb/investors/annual-report/
- Llibre, J. M., Hung, C. C., Brinson, C., et al. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in HIV-1-infected adults: 100-week results of the SWORD-1 and SWORD-2 trials. The Lancet HIV, 5(6), e333-e344.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
